The overall goal of this education session is to equip cardiologists and relevant healthcare team members with the knowledge and tools necessary to improve the early recognition, accurate diagnosis, and effective treatment of cardiac amyloidosis and optimize patient outcomes.
Accreditation Statement
In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page.
Joint Accreditation Statement:
In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nurses:
The ACCF designates this educational activity for a maximum of 1.5 continuing nursing education contact hours.
Credit Designation Statement:
Physicians:
The ACCF designates this internet enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associates:
AAPA Credit Designation Statement – Enduring Materials
The American College of Cardiology Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1.5 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 04/18/2026 PAs should only claim credit commensurate with the extent of their participation.
Pharmacists:
ACCF designates this continuing education activity for 1.5 contact hours of the Accreditation Council for Pharmacy Education. ACPE Universal Activity Number (UAN): JA4008225-0000-25-011-H01-P (Pharmacists); JA4008225-0000-25-011-H01-T (Pharmacist Technicians).
Interprofessional Continuing Education (ICPE) Credit:
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Target Audience:
This course is intended for physicians, nurses, pharmacists, physician associates and the cardiovascular care team.
Important Dates:
Date of Release: April 18, 2025
Term of Approval/Date of Credit Expiration: April 18, 2026
Learner Objectives:
Upon completion of this program, attendees should be able to:
- Recognize the diverse clinical presentations of cardiac amyloidosis emphasizing the need for early detection and differentiation from other conditions.
- Describe the appropriate diagnostic workup for suspected cardiac amyloidosis.
- Describe how to effectively incorporate novel therapies into treatment plans.
- Discuss emerging advancements in the diagnosis and treatment of cardiac amyloidosis, including ongoing clinical trials and novel imaging agents.
- Employ multidisciplinary approaches for developing effective care pathways.
Grant Acknowledgement:
Supported by educational grants from Alnylam, AstraZeneca, and BridgeBio Pharma, Inc.
Faculty:
Ronald Witteles, MD, FACC
Amrut Ambardekar, MD, FACC
Justin Lee Grodin, MD, MPH, FACC
Margot Davis, MD
Robert Lee Page, PharmD